Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Kremlin says Lebanon pager blasts risk igniting tensions in 'explosive' region Merck, a leading science and technology company, launched the first single-use reactor specifically designed to ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Gordon Campbell Like the arms race, the funding of new cancer drugs is an endless upwards spiral. First though, the good news ...

Drawing on this extensive experience, we are now ready to accelerate the production of antibody-drug ... made of Ultimus ® ...